Amicogen Inc operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Amicogen Inc with three other
companies in this sector in KOREA (SOUTH) :
Hwail Pharmaceutical Company Limited
sales of 108.74 billion Korean Won [US$98.63 million]
Samil Pharmaceutical Co., Ltd.
(121.11 billion Korean Won [US$109.84 million]
Ctc Bio, Incorporation.
(136.12 billion Korean Won [US$123.46 million]
of which 80%
was Animal Medication).
Amicogen Inc reported sales of 115.18 billion Korean Won (US$104.47 million)
December of 2019.
increase of 21.9%
versus 2018, when the company's sales were 94.52 billion Korean Won .
Sales at Amicogen Inc have increased during each of the previous five years
(and since 2014, sales have increased a total of 321%).
Sales of Health Functional Food saw an increase
that was more than double the company's growth rate: sales were up
60.6% in 2019, from
17.37 billion Korean Won to 27.89 billion Korean Won .
Amicogen Inc also saw significant increases in sales in
Cefdinir (up 44.7% to 7.55 billion Korean Won )
Enzyme (up 30.1% to 7.18 billion Korean Won )
Not all segments of Amicogen Inc experienced an increase in sales in 2019:
sales of Ceftiofur fell 32.5% to 9.42 billion Korean Won .